Riskpilot← Back to searchSign inGet full accessMY-SL INNOVATIONS AB
ABActiveOrg 5591374441Monsungatan 55General medical practice activities · NACE 8621Est. 20171 employees
Revenue 2024
SEK 652K
+281% vs 2023
EBITDA margin
68.3%
+3323% vs 2023
Equity ratio
58.6%
Financial strength
Net profit 2024
SEK 268K
+1471% vs 2023
| Revenue | SEK 652K | +281% |
| EBITDA | SEK 446K | +3323% |
| Net profit | SEK 268K | +1471% |
| Total assets | SEK 1,6M | -4% |
| Equity | SEK 930K | +40% |
| Employees | 1 | — |
Legal name
MY-SL INNOVATIONS AB
Org number
5591374441
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
5 december 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-11-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
FÖREMÅLET FÖR BOLAGETS VERKSAMHET ÄR KONSULTTJÄNSTER SÅSOM BEMANNING, VERKSAMHETSUTVECKLING TILL APOTEKS-, HÄLSO- OCH VÅRDSEKTOR. BOLAGET SKALL ÄVEN BEDRIVA BOKFÖRLAGSVERKSAMHET OCH FÖRSÄLJNING AV BÖCKER.
Address
Monsungatan 55
Email
aloleiw@me.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 320 | 924 | 571 | 171 | 652 |
| Staff expenses | — | −423 | −44 | −0 | −0 |
| EBITDA | 514 | 120 | −10 | −14 | 446 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 514 | 120 | −10 | −14 | 446 |
| Net financials | −1 | −29 | −101 | −6 | 1 |
| Profit before tax | 382 | 90 | 20 | −20 | 336 |
| Tax | −85 | −23 | −29 | — | −69 |
| Net profit | 297 | 68 | −9 | −20 | 268 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 153 | 2 276 | 1 648 | 1 650 | 1 587 |
| Equity | 623 | 691 | 682 | 663 | 930 |
| Long-term debt | 138 | 293 | 30 | 0 | — |
| Short-term debt | 1 261 | 1 161 | 936 | 987 | 547 |
| Total debt | 1 399 | 1 454 | 966 | 987 | 547 |
EBITDA margin
68.3%
This company
15.8%
Market median
+332% vs market
20202024
Equity ratio
58.6%
This company
38.2%
Market median
+53% vs market
20202024
Return on equity
28.8%
This company
18.4%
Market median
+57% vs market
20202024
Net profit margin
41.0%
This company
8.1%
Market median
+406% vs market
20202024
Asset turnover
0.41×
This company
1.12×
Market median
-63% vs market
20202024
Debt / equity
0.71×
This company
0.62×
Market median
+15% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-12-01 – 2024-11-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-11-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-12-01 – 2020-11-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
YM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MY-SL INNOVATIONS AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yassir Mohammed Hussein Al-Oleiw | Chief Executive Officer | 0 companies |
| Samer Al-Dury | Deputy Board Member | 0 companies |